Search
for
Sort by
Research 571–600 of 1000+
- 153 Effectiveness of OR-101, a next generation highly selective JAK3 inhibitor, in a humanized murine model of alopecia areata
- 1108 Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata
- ORAL TOFACITINIB IN MODERATE AND SEVERE ALOPECIA AREATA: CASE SERIES OF 14 PATIENTS
- The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1
- Efficacy of Postbiotics in a PRP-Like Cosmetic Product for the Treatment of Alopecia Area Celsi: A Randomized Double-Blinded Parallel-Group Study
- Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus
- Interleukin-15 and Tumor Necrosis Factor-α in Iraqi Patients with Alopecia Areata
- Efficacy and Safety of Long‐Term Azathioprine Therapy for Severe Alopecia Areata: A 10‐Year Cohort Study
- Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
- Efficacy of mesalazine in children with moderate to severe alopecia areata: case series of 18 patients
- ISID1373 - Expression of programmed cell death 1 inversely correlated with the density of CD8+ T cells infiltrating hair follicles in alopecia areata
- 1373 Expression of programmed cell death 1 inversely correlated with the density of CD8+ T cells infiltrating hair follicles in alopecia areata
- LB1048 Effectiveness of OR-101 in a murine model of atopic dermatitis
- Therapeutics for COVID-19 and post COVID-19 complications: An update
- Real-life effectiveness and safety of baricitinib in 17 Japanese patients with alopecia areata: a 60-week single center study
- Evaluation of the level of serum Interleukins (IL-2, IL-4, IL-15 andIL-17) and its relationship with disease severity in patients with alopecia areata
- IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans
- Contributions of dermatologists to COVID ‐19 research: A brief systematic review
- Incipient Diabetes Mellitus and Nascent Thyroid Disease Presenting as Beard Alopecia Areata: Case Report and Treatment Review of Alopecia Areata of the Beard
- Platelet-rich plasma in the treatment of alopecia areata: A retrospective evaluation of 17 patients
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- Case Report: Alopecia areata in an adolescent after COVID-19 infection
- Case Report: Multimodal contact immunotherapy in alopecia areata: long-term clinical experience in the JAK inhibitor era
- Clinical characteristics, subtype classification, and prognostic factors of ophiasis: A retrospective study of 150 patients with therapeutic implications
- Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
- T <sub>H</sub> 1 effector CD4 T cells rely on IFN-γ production to induce alopecia areata
- Baricitinib in the Management of Severe Alopecia Areata: A Report of Two Cases With Sustained Clinical Response
- A Single Subcutaneous Dose of BMD-1141 Stimulates Hair Regrowth Comparable to Daily, High-Dose Ruxolitinib in a Mouse Model of Alopecia Areata.
- Efficacy and safety of tofacitinib in pediatric patients with alopecia areata: A prospective cohort study
- Top 10 Facts: Common Hair Loss Causes and Management in Patients